RNS : FOR IMMEDIATE RELEASE |
9 NOVEMBER 2016
|
NOTIFICATION OF MAJOR INTEREST BY LEGAL & GENERAL
ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc ("L&G") confirming its holding in ImmuPharma of 4,285,714 million Ordinary Shares in the capital of the Company, representing 3.43% of ImmuPharma's total voting rights.
Commenting, Tim McCarthy, Chairman of ImmuPharma, said: "We are delighted to be able to disclose Legal & General as one of the new significant and major institutional investors which participated in ImmuPharma's recent successful vendor placing. One of the Board's priorities is to maintain and strengthen our shareholder base. We are therefore delighted that such a highly regarded institution as Legal & General has demonstrated its support for ImmuPharma."
Full disclosure of the TR1 is shown below:
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES |
||||
|
|
|||
1. Identity of the issuer or the underlying issuer
|
Immupharma Plc |
|||
2. Reason for the notification (please tick the appropriate box or boxes): |
||||
An acquisition or disposal of voting rights |
Yes |
|||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.
|
|
|||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
|
|
|||
An event changing the breakdown of voting rights |
Yes |
|||
Other (please specify):
|
Placement of 2,857,143 shares |
|
||
3. Full name of person(s) subject to the |
Legal & General Group Plc (L&G) |
|||
4. Full name of shareholder(s) |
Legal & General Assurance Society Limited (LGAS & LGPL)
|
|||
5. Date of the transaction and date on
|
21 October 2016 |
|||
6. Date on which issuer notified: |
28 October 2016 |
|||
7. Threshold(s) that is/are crossed or
|
L&G (Above 3%) |
|||
8. Notified details:
|
||||||||||||||||
A: Voting rights attached to shares |
||||||||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
||||||||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights |
||||||||||||
Direct |
Indirect |
Direct |
Indirect |
|||||||||||||
ORD GBP 0.10 |
First notification under DTR Sourcebook |
4,285,714 |
4,285,714 |
- |
3.43% |
- |
||||||||||
|
||||||||||||||||
B: Qualifying Financial Instruments |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
||||||||||||
|
|
|
|
|
||||||||||||
|
||||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial
|
Exercise price |
Expiration date |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights
|
|||||||||||
|
|
|
|
|
Nominal |
Delta |
||||||||||
|
|
|||||||||||||||
|
||||||||||||||||
Total (A+B+C) |
||||||||||||||||
Number of voting rights |
Percentage of voting rights |
|||||||||||||||
4,285,714
|
3.43% |
|||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or the |
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
Proxy Voting: |
||||||||||||||||||||||||||
10. Name of the proxy holder: |
N/A |
|||||||||||||||||||||||||
11. Number of voting rights proxy holder will cease |
N/A |
|||||||||||||||||||||||||
12. Date on which proxy holder will cease to hold |
N/A |
|||||||||||||||||||||||||
|
||||||||||||||||||||||||||
|
Notification using the total voting rights figure of 124,638,362 |
|||||||||||||||||||||||||
14. Contact name: |
Victoria Davies (LGIM) |
|||||||||||||||||||||||||
15. Contact telephone number: |
029 2035 4147 |
|||||||||||||||||||||||||
-Ends-
For further information please contact:
|
|